Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Climb Bio, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- 0 vs. Q3 2023
- Shares held
- 16.9M
- +125.1K (+0.7%) vs. Q3 2023
- Total value
- $45.5M
- +$1.51M (+3.4%) vs. Q3 2023
- New holders
- 3
- 4 more added
- Sold out
- 3
- 8 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CLYM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 108 | $734.3M |
| Q1 2026 | 80 | $221.2M |
| Q4 2025 | 65 | $157.4M |
| Q3 2025 | 68 | $89.7M |
| Q2 2025 | 69 | $61.9M |
| Q1 2025 | 76 | $63.4M |
| Q4 2024 | 80 | $100.3M |
| Q3 2024 | 71 | $278.2M |
| Q2 2024 | 47 | $354.8M |
| Q1 2024 | 21 | $46.2M |
| Q4 2023 | 23 | $45.5M |
| Q3 2023 | 23 | $44.0M |
| Q2 2023 | 22 | $46.8M |
| Q1 2023 | 19 | $48.4M |
| Q4 2022 | 20 | $61.0M |
| Q3 2022 | 22 | $47.8M |
| Q2 2022 | 29 | $45.7M |
| Q1 2022 | 43 | $146.8M |
| Q4 2021 | 35 | $181.8M |
| Q3 2021 | 32 | $310.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Climb Bio, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 36 | $0 | 0.00% | −20−35.7% | Reduced |
| JPMorgan Chase & Co | 1 | $3 | 0.00% | +1 | New |
| Bank of America Corp | 3 | $8 | 0.00% | −1,387−99.8% | Reduced |
| Wells Fargo & Company | 48 | $130 | 0.00% | +3+6.7% | Added |
| Qube Research & Technologies Ltd | 981 | $2.63K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,709 | $4.61K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,455 | $9.33K | 0.00% | −441−11.3% | Reduced |
| Advisor Group Holdings, Inc. | 8,333 | $22.5K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 10,603 | $29.0K | 0.00% | +10,603 | New |
| Chicago Partners Investment Group LLC | 12,160 | $36.2K | 0.00% | −646−5.0% | Reduced |
| Cerity Partners LLC | 13,821 | $37.3K | 0.00% | +13,821 | New |
| Millennium Management LLC | 18,423 | $49.4K | 0.00% | −39,913−68.4% | Reduced |
| State Street Corp | 21,700 | $58.2K | 0.00% | 00.0% | Unchanged |
| Tudor Investment Corp Et Al | 29,490 | $79.6K | 0.00% | −214−0.7% | Reduced |
| BlackRock Inc. | 31,145 | $84.1K | 0.00% | −166−0.5% | Reduced |
| Northern Trust Corp | 48,712 | $131.5K | 0.00% | +37,530+335.6% | Added |
| Bridgeway Capital Management, LLC | 55,223 | $148.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 66,626 | $178.6K | 0.00% | 00.0% | Unchanged |
| Atom Investors LP | 78,276 | $211.3K | 0.04% | −610−0.8% | Reduced |
| Vanguard Group Inc | 310,486 | $838.3K | 0.00% | +665+0.2% | Added |
| Driehaus Capital Management LLC | 811,680 | $2.19M | 0.03% | 00.0% | Unchanged |
| BML Capital Management, LLC | 2,180,000 | $5.89M | 4.65% | +241,737+12.5% | Added |
| Ra Capital Management, L.P. | 13,150,849 | $35.5M | 0.55% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −121,110−100.0% | Sold out |
| Stifel Financial Corp | 0 | $0 | 0.00% | −14,650−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −89−100.0% | Sold out |